Atezolizumab (neoadjuvant with nab-paclitaxel) for early triple negative breast cancer (ID1574)

£656.3K GBP

Funder	National Institute for Health Research
Recipient Organization	University of Liverpool.
Country	United Kingdom
Start Date	Apr 20, 2021
End Date	Oct 05, 2021
Duration	168 days
Number of Grantees	1
Roles	Award Holder
Data Source	Europe PMC
Grant ID	`NIHR134026`

Grant Description

To appraise the clinical and cost effectiveness of atezolizumab within its marketing authorisation for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer.